Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Jul;61(7):1581-1591.
doi: 10.1007/s00125-018-4619-x. Epub 2018 May 4.

Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial

Paul Welsh  1 , Naomi Rankin  2 , Qiang Li  3 , Patrick B Mark  2 , Peter Würtz  4   5 , Mika Ala-Korpela  6   7   8   9   10 , Michel Marre  11   12   13 , Neil Poulter  14 , Pavel Hamet  15   16   17 , John Chalmers  3 , Mark Woodward  3   18   19 , Naveed Sattar  2
Affiliations
Randomized Controlled Trial

Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial

Paul Welsh et al. Diabetologia. 2018 Jul.

Abstract

Aims/hypotheses: We aimed to quantify the association of individual circulating amino acids with macrovascular disease, microvascular disease and all-cause mortality in individuals with type 2 diabetes.

Methods: We performed a case-cohort study (N = 3587), including 655 macrovascular events, 342 microvascular events (new or worsening nephropathy or retinopathy) and 632 all-cause mortality events during follow-up, in a secondary analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study. For this study, phenylalanine, isoleucine, glutamine, leucine, alanine, tyrosine, histidine and valine were measured in stored plasma samples by proton NMR metabolomics. Hazard ratios were modelled per SD increase in each amino acid.

Results: In models investigating associations and potential mechanisms, after adjusting for age, sex and randomised treatment, phenylalanine was positively, and histidine inversely, associated with macrovascular disease risk. These associations were attenuated to the null on further adjustment for extended classical risk factors (including eGFR and urinary albumin/creatinine ratio). After adjustment for extended classical risk factors, higher tyrosine and alanine levels were associated with decreased risk of microvascular disease (HR 0.78; 95% CI 0.67, 0.91 and HR 0.86; 95% CI 0.76, 0.98, respectively). Higher leucine (HR 0.79; 95% CI 0.69, 0.90), histidine (HR 0.89; 95% CI 0.81, 0.99) and valine (HR 0.79; 95% CI 0.70, 0.88) levels were associated with lower risk of mortality. Investigating the predictive ability of amino acids, addition of all amino acids to a risk score modestly improved classification of participants for macrovascular (continuous net reclassification index [NRI] +35.5%, p < 0.001) and microvascular events (continuous NRI +14.4%, p = 0.012).

Conclusions/interpretation: We report distinct associations between circulating amino acids and risk of different major complications of diabetes. Low tyrosine appears to be a marker of microvascular risk in individuals with type 2 diabetes independently of fundamental markers of kidney function.

Trial registration: ClinicalTrials.gov NCT00145925.

Keywords: Amino acid; Diabetes complications; Metabolomics; Risk factors; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

JC has received Research grants from Servier as Principal investigator for ADVANCE and for the ADVANCE-ON post trial follow-up study and honoraria from Servier for speaking about these studies at scientific meetings. MW reports receiving consulting fees from Amgen. PWu is an employee and shareholder of Nightingale Health Ltd, which conducted the biomarker quantification. All other authors declare that there is no duality of interest associated with their contribution to this paper.

Figures

Fig. 1
Fig. 1
Flow diagram for design and sample analysis in the ADVANCE study of amino acids (note microvascular, macrovascular and all-cause mortality not mutually exclusive)
Fig. 2
Fig. 2
Adjusted associations (model 2, log10 scale HR) of amino acids individually (per 1 SD increase) with macrovascular outcomes (a), microvascular outcomes (b) and all-cause mortality (c)
See this image and copyright information in PMC

Comment in

References

    1. Gaillard T, Osei K. Ethnic differences in serum lipids and lipoproteins in overweight/obese African-American and white American women with pre-diabetes: significance of NMR-derived lipoprotein particle concentrations and sizes. BMJ Open Diabetes Res Care. 2016;4:e000246. doi: 10.1136/bmjdrc-2016-000246. - DOI - PMC - PubMed
    1. Liggi S, Griffin JL. Metabolomics applied to diabetes-lessons from human population studies. Int J Biochem Cell Biol. 2017;93:136–147. doi: 10.1016/j.biocel.2017.10.011. - DOI - PubMed
    1. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17:448–453. doi: 10.1038/nm.2307. - DOI - PMC - PubMed
    1. Floegel A, Stefan N, Yu Z, Mühlenbruch K, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2013;62:639–648. doi: 10.2337/db12-0495. - DOI - PMC - PubMed
    1. Tillin T, Hughes AD, Wang Q, et al. Diabetes risk and amino acid profiles: cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent REvisited) Study. Diabetologia. 2015;58:968–979. doi: 10.1007/s00125-015-3517-8. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data